Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?

Annals of Surgery

Volumn 252, Issue 5, 2010, Pages 774-785

  Adam, Rene ^a   Bhangui, Prashant ^a   Poston, Graeme ^b   Mirza, Darius ^c   Nuzzo, Gennaro ^d   Barroso, Eduardo ^e   Ijzermans, Jan ^f   Hubert, Catherine ^g   Ruers, Theo ^h   Capussotti, Lorenzo ⁱ   Ouellet, Jean Francois ^j   Laurent, Christophe ^k   Cugat, Esteban ^l   Colombo, Pierre Emmanuel ^m   Milicevic, Miroslav ⁿ  

^a HÔPITAL PAUL BROUSSE   (France)

^b University Hospitals Aintree   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d CATHOLIC UNIVERSITY   (Italy)

^e HOSPITAL CURRY CABRAL   (Portugal)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Hôpital Saint Luc   (Belgium)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ MAURIZIANO HOSPITAL   (Italy)

^j LAVAL UNIVERSITY   (Canada)

^k HÔPITAL SAINT ANDRÉ   (France)

^l HOSPITAL MÚTUA DE TERRASSA   (Spain)

^m CRLC   (France)

ⁿ Clinic for Digestive Surgery   (Serbia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

AGED; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR VOLUME; ADULT; AGE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL SURGERY; LIVER SURGERY; MULTICENTER STUDY; PERIOPERATIVE PERIOD; PREOPERATIVE TREATMENT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOEMBRYONIC ANTIGEN; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASMS, SECOND PRIMARY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SURVIVAL RATE;

EID: 78349300856     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181fcf3e3     Document Type: Conference Paper

References (44)

1. Fortner JG, Silva JS, Golbey RB, et al. Multivariateanalysisofapersonalseries of247 consecutive patients with liver metastases from colorectal cancer, part 1: treatmentbyhepatic resection. Ann Surg. 1984;199:306-316
2. Bengmark S, Hafstrom L. The natural history ofprimary and secondary malig-nant tumours of the liver, part I: the prognosis for patients with hepatic metas-tases from colonic andrectalcarcinomaby laparotomy Cancer. 1969;23:198-202.
3. Fong Y, Kemeny N, Paty P, et al. Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol. 1996;12:219-252.
4. Kemeny N, Fata F Arterial, portal or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J Hepatobiliary Pancreat Surg. 1999;6:39-49.
5. Steele GJ, Ravikumar TS. Resection ofhepatic metastases from colorectal metastases: biologic perspectives. Ann Surg. 1989;210:127-138.
6. Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668S-676S.
7. Curley SA. Outcomes after surgical treatment of colorectal cancer liver metas-tases. Semin Oncol. 2005;32:S109-111.
8. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-946.
9. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol. 2005;23:8490-8499.
10. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site ofrecurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715-722.
11. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825.
12. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after re-section of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 orodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-447.
13. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-657.
14. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized con-trolledtrial. Lancet. 2008;371:1007-1016.
15. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7:1034-1044.
16. Fong Y, Bentrem DJ. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg. 2006;243:8-9.
17. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460-466.
18. Anderson CD, Chari RS. Chemotherapy liver injury. Surgery. 2010;147:195-196
19. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983-4990.
20. Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for col-orectal liver metastases: impact on hepatic histology and postoperative out-come. J Gastrointest Surg. 2007;11:860-868.
21. Nordlinger B, Cutsem EV, Gruenberger T, et al. Combination ofsurgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985-992.
22. Petrelli NJ. Perioperative or postoperative therapy for resectable colorectal hepatic metastases. J Clin Oncol. 2008;26:4862-4863.
23. Chua TC, Saxena A, Liauw W, et al. Systematic review ofrandomized and nonrandomized trials of the clinical response and outcomes of preoperative systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol. 2010;17:492-501.
24. Gallagher DJ, Zheng J, Capanu M, et al. Response to preoperative chemother-apy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol. 2009;16:1844-1851.
25. Reddy SK, Zorzi D, Lum YW, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. 2009;16:1809-1819.
26. Lubezky N, Geva R, Shmueli E, et al. Is there a survival benefit to preopera-tive versus postoperative chemotherapy combined with surgery for resectable colorectallivermetastases? World J Surg. 2009;33:1028-1034.
27. Bathe OF, Ernst S, Sutherland FR, et al. Aphase II experience withpreoperative irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer. 2009;20(9):156.
28. Gruenberger B, Scheithauer W, Punzengruber R, et al. Importance ofresponse to preoperative chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer. 2008;8:120.
29. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635-1641.
30. Blazer DG III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection ofhepatic colorectal metastases. J Clin Oncol. 2008;26:5344-5351.
31. Small RM, Lubezky N, Shmueli E, et al. Response to chemotherapy predicts survival following resection ofhepatic colorectal metastases in patients treated with preoperative therapy J Surg Oncol. 2009;99:93-98.
32. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine and oxaliplatin as preoperative therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-1835.
33. Scoggins CR, Campbell ML, Landry CS, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol. 2009;16:35-41.
34. Welsh FKS, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96:1037-1042.
35. Malik HZ, Farid S, Al-Mukthar A, et al. A critical appraisal of the role of preoperative chemotherapy for colorectal liver metastases: a case-controlled study. Ann Surg Oncol. 2007;14:3519-3526.
36. Aloysius MM, Zaitoun AM, Beckingham IJ, et al. The pathological response to preoperative chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. Virchows Arch. 2007;451:943-948.
37. Chun YS, Vauthey J-N, Ribero D, et al. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety andsurvival. J Gastrointest Surg. 2007;11:1498-1504.
38. Hewes JC, Dighe S, Morris RW, et al. Preoperative chemotherapy and the out-come ofliver resection for colorectal metastases. World J Surg. 2007;31:353-364.
39. Tamandl D, Gruenberger B, Herberger B, et al. Selective resection of colorectal livermetastases. Eur J Surg Oncol. 2007;33:174-182.
40. Sperti E, Faggiuolo R, Gerbino A, et al. Outcome of metastatic colorectal cancer: analysis of a consecutive series of229 patients. the impact of a multi-disciplinary approach. Dis Colon Rectum. 2006;49:1596-1601.
41. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemother-apy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052-1061.
42. Allen PJ, Kemeny N, Jarnagin W, et al. Importance ofresponse to preoperative chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109-115.
43. Tanaka K, Adam R, Shimada H, et al. Role ofpreoperative chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90:963-969.
44. Wein A, Riedel C, Bruckl W, et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in pa-tients with primary resectable liver metastases of colorectal cancer. Oncology. 2003;64:131-138.